Literature DB >> 10712254

Fas and Fas ligand in gut and liver.

M J Pinkoski1, T Brunner, D R Green, T Lin.   

Abstract

Apoptosis (programmed cell death) has been shown to play a major role in development and in the pathogenesis of numerous diseases. A principal mechanism of apoptosis is molecular interaction between surface molecules known as the "death receptors" and their ligands. Perhaps the best-studied death receptor and ligand system is the Fas/Fas ligand (FasL) system, in which FasL, a member of the tumor necrosis factor (TNF) family of death-inducing ligands, signals death through the death receptor Fas, thereby resulting in the apoptotic death of the cell. Numerous cells in the liver and gastrointestinal tract have been shown to express Fas/FasL, and there is a growing body of evidence that the Fas/FasL system plays a major role in the pathogenesis of many liver and gastrointestinal diseases, such as inflammatory bowel disease, graft vs. host disease, and hepatitis. Here we review the Fas/FasL system and the evidence that it is involved in the pathogenesis of liver and gastrointestinal diseases.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10712254     DOI: 10.1152/ajpgi.2000.278.3.G354

Source DB:  PubMed          Journal:  Am J Physiol Gastrointest Liver Physiol        ISSN: 0193-1857            Impact factor:   4.052


  37 in total

Review 1.  Receptor-mediated control of regulatory volume decrease (RVD) and apoptotic volume decrease (AVD).

Authors:  Y Okada; E Maeno; T Shimizu; K Dezaki; J Wang; S Morishima
Journal:  J Physiol       Date:  2001-04-01       Impact factor: 5.182

2.  Hepatoprotection via the IL-6/Stat3 pathway.

Authors:  Rebecca Taub
Journal:  J Clin Invest       Date:  2003-10       Impact factor: 14.808

3.  Endothelial Fas-Ligand in Inflammatory Bowel Diseases and in Acute Appendicitis.

Authors:  Tuomo S Kokkonen; Tuomo J Karttunen
Journal:  J Histochem Cytochem       Date:  2015-09-15       Impact factor: 2.479

4.  Smad3 reduces susceptibility to hepatocarcinoma by sensitizing hepatocytes to apoptosis through downregulation of Bcl-2.

Authors:  Yu-An Yang; Gen-Mu Zhang; Lionel Feigenbaum; Ying E Zhang
Journal:  Cancer Cell       Date:  2006-06       Impact factor: 31.743

Review 5.  Death receptor signal transducers: nodes of coordination in immune signaling networks.

Authors:  Nicholas S Wilson; Vishva Dixit; Avi Ashkenazi
Journal:  Nat Immunol       Date:  2009-03-19       Impact factor: 25.606

6.  The role of apoptosis in immune hyporesponsiveness following AAV8 liver gene transfer.

Authors:  Susan M Faust; Peter Bell; Yanqing Zhu; Julio Sanmiguel; James M Wilson
Journal:  Mol Ther       Date:  2013-10-15       Impact factor: 11.454

7.  Caspase Inhibition Reduces Hepatic Tissue Factor-Driven Coagulation In Vitro and In Vivo.

Authors:  Anna K Kopec; Alfred P Spada; Patricia C Contreras; Nigel Mackman; James P Luyendyk
Journal:  Toxicol Sci       Date:  2018-04-01       Impact factor: 4.849

8.  A novel transgenic mouse model of lysosomal storage disorder.

Authors:  Sonia Ortiz-Miranda; Rui Ji; Agata Jurczyk; Ken-Edwin Aryee; Shunyan Mo; Terry Fletcher; Scott A Shaffer; Dale L Greiner; Rita Bortell; Ronald G Gregg; Alan Cheng; Leah J Hennings; Ann R Rittenhouse
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2016-09-22       Impact factor: 4.052

9.  Loss of macroautophagy promotes or prevents fibroblast apoptosis depending on the death stimulus.

Authors:  Yongjun Wang; Rajat Singh; Ashish C Massey; Saul S Kane; Susmita Kaushik; Taneisha Grant; Youqing Xiang; Ana Maria Cuervo; Mark J Czaja
Journal:  J Biol Chem       Date:  2007-12-11       Impact factor: 5.157

10.  Serum levels of soluble Fas, soluble tumor necrosis factor-receptor II, interleukin-2 receptor and interleukin-8 as early predictors of hepatocellular carcinoma in Egyptian patients with hepatitis C virus genotype-4.

Authors:  Abdel-Rahman N Zekri; Hanaa M Alam El-Din; Abeer A Bahnassy; Naglaa A Zayed; Waleed S Mohamed; Suzan H El-Masry; Sayed K Gouda; Gamal Esmat
Journal:  Comp Hepatol       Date:  2010-01-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.